Real-world experience of rIX-FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID-19 pandemic.

Autor: Díaz-Jordán BL; Hematology Department Hospital General de Valdepeñas Ciudad Real Spain., Cebanu T; Hematology and Hemostasis Department Hospital Universitario La Paz Madrid Spain., García Barcenilla S; Hospital La Paz Institute for Health Research - IdiPAZ (Hospital Universitario La Paz - Universidad Autónoma de Madrid) Madrid Spain., Álvarez-Román MT; Hematology and Hemostasis Department Hospital Universitario La Paz Madrid Spain.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2023 Nov 28; Vol. 11 (12), pp. e8180. Date of Electronic Publication: 2023 Nov 28 (Print Publication: 2023).
DOI: 10.1002/ccr3.8180
Abstrakt: Switching to rIX-FP prophylaxis at dosing intervals of up to 14 days in a hemophilia B pediatric patient decreased treatment burden by reducing the number of administrations and hospital visits, without affecting efficacy or treatment adherence. This is particularly important in contexts of limited mobility and overloaded healthcare services.
Competing Interests: BLDJ has received honoraria for speaking engagements or funds for research from CSL Behring, Takeda, NovoNordisk, Roche, Daiichi‐Sankyo, Sobi, Fresenius, Leo Pharma, Abbvie, and Janssen. TC has no conflicts of interest to declare. SGB has received honoraria for speaking engagements from Roche, NovoNordisk, CSL Behring, Takeda, Sobi, Biomarin, Novartis, Bayer and Pfizer. MTAR has received honoraria for speaking engagements or consultancy, or funds for research from Takeda, Bayer, CSL Behring, Grifols, Novo Nordisk, Sobi, Octapharma, Roche, Amgen, Novartis, and Pfizer.
(© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje